Zoe Neviere

Caen, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Corrigendum to "Management and survival of patients with cancer of unknown primary discussed by a French national multidisciplinary tumour board: a retrospective analysis" The Lancet Regional Health - Europe, Volume 60, January 2026, 101524.

Corrigendum to "Management and survival of patients with cancer of unknown primary discussed by a French national multidisciplinary tumour board: a retrospective analysis" The Lancet Regional Health - Europe, Volume 60, January 2026, 101524.

Journal: The Lancet regional health. Europe

Published: July 30, 2026

Role of a National Multidisciplinary Tumor Board in the diagnostic and therapeutic management of patients with cancers of unknown primary (CUP)

Role of a National Multidisciplinary Tumor Board in the diagnostic and therapeutic management of patients with cancers of unknown primary (CUP)

Journal: Bulletin du cancer

Published: December 23, 2025

Management and survival of patients with cancer of unknown primary discussed by a French national multidisciplinary tumour board: a retrospective analysis.

Management and survival of patients with cancer of unknown primary discussed by a French national multidisciplinary tumour board: a retrospective analysis.

Journal: The Lancet regional health. Europe

Published: July 07, 2025

Case report: Musculoskeletal metastastic inflammatory myofibroblastic tumor (IMT) treated by sequential ALK-TKI with longterm response.

Case report: Musculoskeletal metastastic inflammatory myofibroblastic tumor (IMT) treated by sequential ALK-TKI with longterm response.

Journal: Frontiers in oncology

Published: October 02, 2024

Potential of PSMA for breast cancer in nuclear medicine: digital quantitative immunohistochemical analysis and implications for a theranostic approach.

Potential of PSMA for breast cancer in nuclear medicine: digital quantitative immunohistochemical analysis and implications for a theranostic approach.

Journal: BMC cancer

Published: March 04, 2024

Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial.

Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial.

Journal: Therapeutic advances in urology

Published: June 27, 2023

Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.

Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.

Journal: The Lancet. Oncology

Published: March 03, 2023

Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer According to Somatic Damage DNA Repair Gene Alterations.

Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer According to Somatic Damage DNA Repair Gene Alterations.

Journal: Current oncology (Toronto, Ont.)

Published: March 11, 2022

TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma.

TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma.

Journal: BMC cancer

Published: December 23, 2021

Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects.

Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 14, 2021

Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: A powerful approach.

Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: A powerful approach.

Journal: American journal of human genetics

Published: June 15, 2021

Platinum-induced nausea and vomiting in patients treated for head and neck cancer.

Platinum-induced nausea and vomiting in patients treated for head and neck cancer.

Journal: Bulletin du cancer

Published: September 01, 2020

Showing 1-12 of 15

Last Updated: 09/26/2026